Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors

• Published in: Trends in pharmacological sciences (Regular ed.) Vol. 11; no. 4; p. 150
• Main Authors: Beavo, J A, Reifsnyder, D H
• Format: Journal Article
• Language: English
• Published: England 01.04.1990
• Subjects: 2',3'-Cyclic-Nucleotide Phosphodiesterases - analysis; 2',3'-Cyclic-Nucleotide Phosphodiesterases - antagonists & inhibitors; Animals; Drug Design; Humans; Isoenzymes; Phosphodiesterase Inhibitors
• ISSN: 0165-6147
• DOI: 10.1016/0165-6147(90)90066-H

Primary sequence information has been reported for more than 15 different mammalian cyclic nucleotide phosphodiesterases. Moreover, recent observations suggest that many of these isozymes are selectively expressed in a limited number of cell types. The fact that nearly all these different phosphodiesterases have unique primary sequences in their catalytic or regulatory domains and that they are often selectively expressed implies that it may be possible to modulate individual isozymes using specific drugs. Joe Beavo and David Reifsnyder summarize much of the evidence that has led to our current understanding of multiple isozymes of phosphodiesterase, with emphasis on aspects that may be relevant to drug design. They also discuss why many previous attempts to isolate isozyme-selective inhibitors may have failed.